Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1816 to 1830 of 7707 results

  1. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838

    Awaiting development [GID-TA11275] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 TS ID 11839

    Awaiting development [GID-TA11276] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190

    Awaiting development [GID-TA11283] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years TS ID 11819

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]

      Status ...

    Technology appraisal guidance
    Topic selection

  6. CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666

    Awaiting development [GID-TA11182] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. DV7103 for treating cystinuria in people 6 months and over TS ID 10438

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

    In development [GID-HST10033] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  9. Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652

    Awaiting development [GID-TA11194] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523

    Awaiting development [GID-TA11114] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781

    Awaiting development [GID-TA11110] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]

    Awaiting development [GID-TA10885] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683

    Awaiting development [GID-TA11053] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736

    Awaiting development [GID-TA11076] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]

      Status ...

    Technology appraisal guidance
    Topic selection